Jean‐Claude Sirard

This study evaluates the tolerance and innate immune response of human respiratory epithelial cells to FLAMOD, a flagellin-based therapy, showing dose-dependent activation of immune pathways without tissue damage.

This study shows that nebulized FLAMOD, a flagellin agonist, induces a robust immune response in pigs without adverse effects, highlighting innate immunity and bacterial defense pathways.

This study shows flagellin activates TLR5 in human airway epithelium, enhancing immune responses in both healthy and diseased states, but not directly reducing bacterial load.

This study shows that combining aerosolized FLAMOD with subtherapeutic penicillin G improves bacterial clearance and reduces lung lesions in pigs infected with Actinobacillus pleuropneumoniae.

This study evaluates nebulized flagellin as a therapeutic for antibiotic-resistant pneumococcal pneumonia, showing it enhances immune response and synergizes with amoxicillin in mice.